Browse > Article

Synthesis of (${\pm}$)-cis-8-amino-l-2,3,4,4a,5,10b-hexahydrothiazolo[4,5-f]indeno [1,2-b][1,4]oxazine  

Ma, Eun-Sook (College of Pharmacy, Catholic University of Daegu)
Publication Information
YAKHAK HOEJI / v.52, no.6, 2008 , pp. 488-493 More about this Journal
Abstract
2-Aminothiazole ring as a bioisoster of catechol in dopamine has provided with good oral availability and lipophilic property. 2-Aminoindan, is a rigid form of dopamine, was evaluated as a dopamine D3 agonist with low neurotoxicity. Dopamine D3 agonist was evaluated as selective for the treatment of Parkinson's disease. In order to develop a novel dopamine D3 agonist, we tried to synthesize the aminothiazoloindenoxazine derivative that is a hybrid structure of aminoindenoxazine and thiazole ring. cis-2-Amino-1-indanol (2) was synthesized from 1,2-indandione-2-oxime by catalytic hydrogenation and it was treated with chloroacetyl chloride and NaH in benzene solution to give (${\pm}$)-cis-4,4a,5,9b-tetrahydroindeno[1,2-b][1,4]oxazin-3(2H)-one (6). Nitration of 6 by the mixed acid gave 8-nitro compound (7) and the carbonyl group of 7 was reduced with $LiAlH_4$ to afford compound (8). 8 was reduced to form (${\pm}$)-cis-8-amino-2,3,4,4a,5,9b-hexahydroindeno[1,2-b][1,4]oxazine (9) and finally it was cyclized with KSCN in glacial acetic acid to yield (${\pm}$)-cis-8-amino-2,3,4,4a,5,10b-hexahydrothiazolo[4,5-f]indeno[1,2-b][1,4]oxazine (10).
Keywords
Parkinson's Disease; Dopamine D3 receptor agonist; Aminothiazoloindenooxazine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kebabian, J. W. and Calne, D. B. : Multiple receptors for dopamine. Nature 277, 93 (1979)   DOI   ScienceOn
2 DeWald, H. A., Heffner, T. G., Jaen, J. C., Lustgarten, D. M., McPhail, A. T., Meltzer, L. T., Pugsley, T. A. and Wise, L. D. : Synthesis and dopamine agonist properties of (+)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazine-9-ol and its enantiomers. J. Med. Chem. 33, 445 (1990)   DOI   PUBMED
3 Dijkstra, D., Mulder, T. B., Rollema, H., Tepper, P. G., Van der Weide, J. and Horn, A. S. : Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b]-1,4-oxazin-7- and 9-ols: the significance of nitrogen pKa values for central dopamine receptor activation. J. Med. Chem. 31, 2178 (1988)   DOI   PUBMED
4 Bonne, C., Latour, E., Muller, P., Kozak, Y., Fature, J. P., Malet, F., Colin, J., Tissot, M., Giroud, J. P., Maghni, K., Griswold, D. E. and Coquelet, C. : 2-(2-Hydroxy-4-methylphenyl) aminothiazole hydrochloride as a inhibitor of cyclooxygenase and a free radical scavenger. 2nd communication: anti-inflammatory activity. Arzneimittelforschung 39, 1246 (1981)
5 Pugsley, T. A., Davis, M. D., Akunne, H. C., MacKenzie, R. G., Shin, Y. H., Damsma, G., Wikstrom, H., Whetzel, S. Z., Georgic, L. M., Cooke, L. W., Demattos, S. B., Corbin, A. E., Glass, S. A., Wise, L. D., Dijkstra, D. and Heffner, T. G. : Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275, 1355 (1995)   PUBMED
6 Hacksell, U., Arvidsson, L. E., Svensson U., Nilsson, J. L., Wilstrom, H., Lindberg, P., Sanchez, D., Hjorth, S., Carlsson, A. and Paalzow, L. : Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity. J. Med. Chem. 24, 429 (1981)   DOI   PUBMED
7 Levant, B. : The $D_3$ dopamine receptor; Neurobiology and potential clinical relevance. Pharmacol. Rev. 49(3), 231 (1997)   PUBMED
8 Haadsma-Syensson, S. R., Cleek, K. A., Dinh, D. M., Duncan, J. N., haber, C. L., Huff, R. M., Lajiness, M. E., Nichols, N. F., Smith, M. W., Svensson, K. A., Zaya, M. J., Carlsson, A. and Lin, C.-H. : Dopamine D3 receptor antagonists, 1. Synthesis and structure-activity relationshilps of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-1-substituted-2-aminoindans. J. Med. Chem. 44, 4716 (2001)   DOI   ScienceOn
9 Hall, E. D., Andrus, P. K., Oostveen, J. A., Althaus, J. S. and Vonvoigtlander, P. F. : Neuroprotective effects of the dopamine $D_2/D_3$ agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742, 80 (1996)   DOI   PUBMED   ScienceOn
10 Mierau, J., Schnider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E. and Huff, R. M. : Pramipexole binding and activation of cloned and expressed dopamine $D_2,\;D_3\;and\;D_4$ receptor. Eur. J. Pharmacol. 290, 29 (1995)   DOI   ScienceOn
11 Watts, R. L. : The role of dopamine agonists in early Parkinson's disease. Neurology 49, S34 (1997)   DOI
12 James, P. B. Jr. and Montford, E. P. : Pramipexole-a new dopamine agonist for the treatment of Parkinson's disease. J. Neuro. Sci. 163, 25 (1999)   DOI   ScienceOn
13 Jean, J. C., Wise, L. D., Caprathe, B. W., Tecle, H., Bergmeier, S., Humblet, C. C., Heffner, T. G., Meltzer, L. T. and Pugsley, T. A. : 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties. J. Med. Chem. 33, 311 (1990)   DOI   PUBMED